As a follow up to my latest article on Athersys (ATHX), “A Significantly Undervalued Stem Cell Company Approaching Key Catalysts,” here is a candid interview between Blackbird Analytics Founder (Sam) and Athersys CEO Gil Van Bokkelen. This interview goes into great detail about the commercial prospects and scientific approach the company has taken since its inception in 1995.
am: Gil, thanks for taking the time to speak with me today.
Sam: Let’s begin with your background: Stanford, PhD in Genetics, double major in Economics, Molecular Biology. You sound like a whiz kid, are you?
Gil: I’ve never really thought of myself like that. Personally, I think what I did when I was at Cal and then later at Stanford was really for me just a reflection of the fact that I am really passionate about business, medicine, and technology. I chose to pursue